Navigation Links
Amarin to Present at the 10th Annual Needham Healthcare Conference
Date:3/31/2011

MYSTIC, Conn. and DUBLIN, March 31, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Executive Chairman and Chief Executive Officer, Joseph Zakrzewski, will present at 8:40 a.m. EDT on April, 6, 2011 at the 10th Annual Needham Healthcare Conference in New York City. Additionally, Amarin's President, John Thero, will be available at the conference to respond to questions from investors. A live Webcast of the presentation will be available at the following URL:

http://wsw.com/webcast/needham44/amrn/

About Amarin

Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101, the active ingredient in which is ethyl-EPA (ethyl icosapentate). On November 29, 2010, the Company reported positive, statistically significant top-line results from the MARINE trial, the first of its Phase 3 clinical trials of AMR101. In the MARINE trial, AMR101 was investigated as a treatment for very high triglycerides (>500 mg/dL). AMR101 is presently being investigated in a second Phase 3 clinical trial, the ANCHOR trial, for the treatment of patients on statin therapy with high triglycerides (e200 and <500mg/dL) with mixed dyslipidemia. The MARINE trial was, and the ANCHOR trial currently is, conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development.

Investor Contact Information:
Stephen D. Schultz
Investor Relations and Corporate Communications
Amarin Corporation
In U.S.: +1 (860) 572-4979 x292
investor.relations@amarincorp.com

Lee M. Stern
The Trout Group
In U.S.: +1 (646) 378-2922
lstern@troutgroup.com

Media Contact Information:
David Schull or Martina Schwarzkopf, Ph.D.
Russo Partners
In U.S.: +1 (212) 845-4271 or +1 (212) 845-4292 (office)
+1 (347) 591-8785 (mobile)
david.schull@russopartnersllc.com
martina.schwarzkopf@russopartnersllc.com


'/>"/>
SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarin Reports Year-End and Q4 2010 Results
2. Amarin to Present at Two Upcoming Investor Conferences
3. Amarin to Present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
4. Amarin Provides 2010 Year-End Review to Shareholders
5. Amarin Announces Successful Completion of Offering of American Depositary Shares
6. Amarin Announces Underwriters Exercise of Over-Allotment Option
7. Amarin Prices Public Offering of American Depositary Shares
8. Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
9. Amarin Corporation to Host Investor Conference Call on Wednesday, November 10, 2010
10. Amarin to Present at UBS Life Sciences Conference
11. Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
(Date:2/4/2016)... 2016 In response to the opioid abuse epidemic, ... for Medical Products and Tobacco, along with other FDA leaders, ... approach to opioid medications. The plan will focus on policies ... pain access to effective relief. --> ... Re-examine the risk-benefit paradigm for opioids and ensure that the ...
Breaking Medicine Technology:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Steven Tonkinson, ... he has completed every year since it started in 2003. This year, he ran ... attention of fellow runners and NBA team the Miami Heat. , This Sunday, while ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV show, ... much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream on ... week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors - ...
(Date:2/5/2016)... ... 05, 2016 , ... The Muscular Dystrophy Association and Sailormen ... the 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise ... related diseases that severely limit strength and mobility. , Now through March ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... George H. Van Allen have signed a joint enrollment and degree completion agreement. ... pathway toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows ...
(Date:2/5/2016)... ... 2016 , ... US Sports Camps , official operators of Nike Yoga ... kids yoga training. ChildLight Yoga Studio is centrally situated in the picturesque New England ... Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering ...
Breaking Medicine News(10 mins):